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ABSTRACT
Leishmania are protozoan parasites that are transmitted by a sand fly vector.
These parasites affect not only humans but also wild animals including domestic dogs
and rodents, which form an additional challenge and public health problem to control the
disease. Leishmaniasis is an important disease with worldwide distribution, including
Saudi Arabia, the Middle East, and other tropical and subtropical areas around the world.
Due to the expansion of irrigation and agricultural activities, more exposure to sand fly
occurs, which leads to the expansion of leishmaniasis infections as newly emerging
disease.
Emerging drug resistance in leishmaniasis is an additional problem, contributed
by enzymes involved in the detoxification of pharmacological agents and other
xenobiotics. Cytochrome b5 reductase (Cb5r) has a high pharmacological significance
because of its essential role in fatty acid elongation, biosynthesis of cholesterol (humans)
or ergosterol (Leishmania, fungi), and cytochrome P450-mediated detoxification of
xenobiotics. Leishmania Cb5r has seven different isoforms whereas human has only one.
Cb5r-7 isoform in Leishmania has the closest homology to the human Cb5r.
The following three aims of this project are focusing on cloning the Cb5r-7
isoform from Leishmania mexicana, its purification as recombinant protein from E.coli
and its functional characterization as potential pharmacological target against
Leishmania.
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Aim 1:
Cloning of the gene for LmexCb5r-7 isoform from Leishmania mexicana.
1. Genetic engineering of LmexCb5r-7 to truncate and delete the predicted
transmembrane domain in order to produce soluble recombinant protein.
2. Add a 6-His tag before the gene at the amino terminus of LmexCb5r-7 for
subsequent nickel column purification.
3. Amplification of the gene by PCR and cloning into the pET23b expression vector.

Aim 2:
Recombinant expression and purification of LmexCb5r-7 protein in E.coli. Large scale
bacterial expression and His6-tag protein purification by Nickel column chromatography.

Aim 3:
Functional characterization of recombinant LmexCb5r-7 enzyme. Enzyme assays as basis
for kinetic biological characterization and subsequent drug assays.
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INTRODUCTION

Leishmania Life Cycle and Disease
Leishmania are protozoan parasites that are transmitted by a sand fly vector of the
genus Phlebotomus in the old world and Lutzomyia in the new world. These parasites
affect not only humans but also wild animals including domestic dogs and rodents, which
form an additional challenge and public health problem to control the disease. The life
cycle of this parasite has two parts, vector cycle and men cycle. In the vector cycle, the
female sand fly is infected by a blood meal containing round, non-motile amastigotes that
change into motile, elongated flagellated promastigotes in its mid gut. Promastigotes then
multiply by binary vision and migrate to the salivary glands ready to be inoculated with
the next blood meal. In the human cycle, promastigotes inoculated into the bite wound
are engulfed by skin macrophages and transformed into amastigotes that multiply
intracellularly (CDC, 2012a) (Fig. 1).
There are different forms of Leishmania infection depends on the type of
Leishmania. Cutaneous leishmaniasis is the most common form of leishmaniasis, usually
infects the skin causing localized or diffused cutaneous leishmaniasis. The infection is
characterized by a red papule appears at the bite site after about 2-8 weeks and form a
skin lesion (oriental sore) which increases in size gradually and filled with amastigotes.
The lesion can be dry or weeping and it is painless unless a secondary bacterial infection
occurs at the lesion. The lesion usually heals by itself with in a year. Diffused cutaneous
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leishmaniasis is a rare form and occurs when the parasites spread through lymphatic
causing a secondary lesion on the skin with no ulceration, and can be incurable in some
cases (an anergic response). The patient may initiate a hypersensitivity response if the
ulcerated nodules decreased in size and heals leaving a scar. In this case the patient
produces immunity. Cutaneous leishmaniasis is very difficult to cure in HIV individuals.

Figure 1: Leishmania Life Cycle. (CDC, 2012a).

Visceral leishmaniasis is the systematic form of leishmaniasis and can be mild or
sever. It affects the human internal organs and can be fatal if not treated. This form may
also affects the kidneys leading to kidney failure. Patients can be asymptomatic or
symptomatic. Symptoms appear within weeks or months after the sand fly bite. Major
symptoms are: weight loss, decreased blood count causing anemia, hepatomegaly,
splenomegaly, increased level of immunoglobulin in blood, fever, vomiting, and diarrhea.
Darkness of the skin is also a symptom of visceral leishmaniasis known as Kala-azar.

2

Mucocutaneous leishmaniasis is a rare form of the disease. This form appears as
nodules inside the nose, mouth and larynx and can occur after months or year after
healing from cutaneous leishmaniasis (Markell et al, 2006; CDC, 2012a).

Leishmania Species and Geographical Distribution
There have been over 30 species described in Leishmania and at least 20 of them
are pathogenic to mammals. Leishmania disease depends on the species, host immune
response and geographical region (Tab. 1).
Table 1: Clinical Disease, Causative Organism and Geographical Distribution of Leishmaniasis.
Clinical disease
Visceral leishmaniasis

Cutaneous leishmaniasis

Mucocutaneous
leishmaniasis

Causative organism
L.d.donovani

Geographical distribution
China, India, Iran, Sudan, Kenya, Ethiopia

L. infantum

Mediterranean basin

L. chagasi

Brazil, Colombia, Venezuela, Argentina

L. amazonensis

New World

L. tropica

Mediterranean basin, Afghanistan

L. major

Middle East, W. and N. Africa, Kenya

L. aethiopica

Ethiopia

L. mexicana

Central America and Amazon basin

L. braziliensis complex

Brazil, Peru, Ecuador, Columbia, Venezuela

Cutaneous leishmaniasis caused by L. tropica complex (L. major, L. aethiopica,
L. tropica) and L. mexicana complex (L. mexicana, L. pifanoi, L. venezuelensis). Visceral
leishmaniasis (Kala-azar) caused by L.donovani complex (L.donovani, L.infantum and L.
chagasi), L. tropica, and L. amazonensis. Mucocutaneous leishmaniasis caused by L.
braziliensis complex (L. braziliensis, L.panamensis). It is hard to distinguish between the
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morphological structures for all species. Isoenzyme analysis, monoclonal antibodies and
DNA sequencing are used to differentiate between Leishmania species (Markell et al,
2006; CDC, 2012b) (Tab. 1).

Pathology of Leishmaniasis
Cutaneous Leishmaniasis:
After the bite of an infected sand fly, promastigotes enter the skin and transform
to amastigotes in the macrophages. Amastigotes disruption activates the macrophages by
sensitized lymphocytes causing a granulomatous reaction forming a localized nodule.
The nodules get ulcerated when the parasite damage the infected area. Healing of the
ulcer depends on the immune system. Stronger immune system results in a faster healing
(Markell et al, 2006).
Visceral Leishmaniasis:
The main issue with visceral leishmaniasis is the suppression of cell-mediated
immunity resulting in an uncontrolled spread and multiplication of the parasite leading to
serious outcome if untreated. Reticulo-endothelial cell hyperplasia occur when the
mononuclear phagocytic cell accumulate in the invaded tissue. Anemia and
granulocytopenia occur when the white and red blood cells life span is reduced.
Splenomegaly and hepatomegaly resulted from the rapid increase in the number of
reticulo-endothelial cells of the spleen and liver. Splenomegaly can increase the
destruction of white and red blood cells. Repeated infection with pneumonia, tuberculosis
and dysentery are frequent and are the main cause of death in advanced stage of visceral
leishmaniasis (Malla & Mahajan, 2006).
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Mucocutaneous Leishmaniasis:
Ulcerated lesions occur the same as oriental sore but larger and more frequent and
seem to develop metastasis. Secondary infection is responsible for the persistence of the
ulcer and its size (Markell et al, 2006).

Treatment
Treatment of leishmaniasis depends on its form. The main drug used to treat
leishmaniasis is antimony-based drug. Pentavalent antimony is important in inhibiting
glycolytic enzymes and fatty acid oxidation in leishmania amastigotes.
Usually,

cutaneous

leishmaniasis

is

not

treated.

Oral

Ketoconazole,

Stibogluconate (Pentostam), intravenous liposomal Amphotericin B or Pentamidine can
be used to treat cutaneous leishmaniasis. In some cases, plastic surgery is used to treat the
scars. Interferon gamma can be injected intradermally around the lesion to enhance the
healing process. Clotrimazole (1%) is a topical cream and was effective in Saudi Arabia
(Markell et al, 2006).
Treatment of mucocutaneous leishmaniasis is similar to the cutaneous form but
differ in the length of treatment. Cycloguanil pamoate is more effective when given
intramuscularly as it inhibits folic acid (Markell et al, 2006).
Visceral leishmaniasis can be treated by intravenous liposomal Amphotericin B,
Miltefosine (Miltex) or Paromomycin (Humatin); the last two are not available in the US.
Immunocompromised patients can be treated with Allopurinol. A combination of
interferon gamma and antimony can also be used in treating visceral leishmaniasis (Cecil
et al, 2011; CDC, 2012c).

5

These drugs are toxic and have strong side effects, which leads to the urgent need
to develop new drugs.

Epidemiology
Leishmaniasis is an important disease that affects the populations of 88 countries
worldwide, including the Middle East, Central and South America and other tropical and
subtropical areas around the world. Due to the expansion of irrigation and agricultural
activities, more exposure to sand fly occurs, which leads to the expansion of
leishmaniasis infections as newly emerging disease. Sand fly is known to be the natural
vector for all types of leishmaniasis transmission but infection by contact transmission is
also possible in cutaneous leishmaniasis. Infection caused by L. tropica can be
transmitted from person to person by contact transmission while all other forms of
cutaneous leishmaniasis are zoonoses. Mechanical transmission by some types of flies
bite like Stomoxys has also been reported. In some cases blood transfusion can also
transmit the disease if the monocytes were infected with leishmaniasis. In visceral
leishmaniasis, two forms of transmissions were reported, human-to-human transmission
was seen in urban areas but the zoonotic form was seen in rural areas. Humans are an
accidental host. The African Kala-azar forms are different from all other Kala-azar forms
seen anywhere else. It is characterized by a lesion in the legs and shows a healed
ulceration at the infection site (Markell et al, 2006).
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Leishmaniasis in Saudi Arabia
Cutaneous leishmaniasis is the common form of leishmaniasis in Saudi Arabia. It
was recognized as a medical condition in the kingdom since 1950. An epidemic of
cutaneous leishmaniasis occurred in 1973 and reached its plateau in the mid 80’s. In
general, male adults represent 75% of the cases. There are two main species responsible
for cutaneous leishmaniasis in Saudi Arabia depending on the region. Leishmania major
is the causative agent in the Eastern and central regions and is transmitted by P.papatasi
while Leishmania tropica is the causative agent in the Southwest and Western regions
and is transmitted by P.sergenti (Al-Aboud, 2004).
The majority of cases were reported in the Qasim province, which is located in
the central part of the kingdom bordering the Riyadh province (WHO, 2008). The highest
number of cases occurs between August and February while the lowest number of cases
occurs in May and June (Al-Aboud, 2004). Cutaneous leishmaniasis has local names
known as Okhet (sister) ()اخت, Nafra (the rash) ()نفــــرة, Domal (boil) ()دمل, and ElMohtafura (the digger) (( )المحتفـــــــرةAl-Tawfiq & AbuKhamsin, 2004). The percentage of
cases of cutaneous leishmaniasis in 2004 was 20.9% in the ِEastern province, 26.6% in
the Qaseem (Qasim) province, 4.1% in the Riyadh province, 4.1% in the Aseer province,
9.1% in the Hail province and 18.5% in the Medina province (Al-Aboud, 2004) (Fig. 2).
In a study conducted between 1983 and 2004, the highest number of reported
cases of cutaneous leishmaniasis was in 1983 (18,318 cases) and the lowest number of
reported cases was in 2003 (3,842 cases) (Fig. 3).
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Figure 2: Geographical Distribution of Cutaneous Leishmaniasis in Saudi Arabia in 2004.

Figure 3: Reported Cases of Cutaneous Leishmaniasis in Saudi Arabia between 1983-2004.

Male represent the highest number of reported cases of cutaneous leishmaniasis
compared to female patients (Al-Aboud, 2004).
Visceral leishmaniasis (VL) is rare but there are some reported cases in the
Southwestern region mostly in the Jezan province (Fig. 4). Male children represent 69%
of the VL cases (WHO, 2008). L.donovani is the causative agent for visceral
leishmaniasis, which has been found with lower prevalence in the Eastern province of
Saudi Arabia. Between 1990 and 1992, eight soldiers who were veterans of Operation
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Dessert Storm in the Western region of Saudi Arabia were evaluated for visceral
leishmaniasis, which nevertheless did not show the classic signs and symptoms of
visceral leishmaniasis (Kala-azar). After several diagnostic tests, L.tropica was found to
be the causative agent for the visceral leishmaniasis in these 8 soldiers. Until then,
L.tropica has been known to cause cutaneous leishmaniasis but not systemic illness. The
strain of L.tropica that was isolated from the soldiers shared some features with
L.donovani suggesting that the L.tropica strain that causes visceral leishmaniasis is
different from the strain that causes cutaneous leishmaniasis (Magill et al, 1993).

Figure 4: Geographical Distribution of Visceral Leishmaniasis in Saudi Arabia in 2004.

A retrospective study was conducted between 1989 and 1994 in Tabuk (located at
the Northwest province of Saudi Arabia) for the existence of visceral leishmaniasis in
that area. The results suggested that L.tropica has changed its pathogenic role and caused
visceral leishmaniasis in the area (Hanly et al, 1998). In 1994, visceral leishmaniasis
cases in Jezan (Gizan) province was observed more in late spring and summer but fewer
cases in the winter season. Hepatosplenomegaly was rare in patients infected with
L.donovani compared to the African Kala-azar form (Al-Orainey et al, 1994). Reported
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cases of visceral leishmaniasis between 1984 and 2004 showed the highest number in
1989 with 305 cases while the lowest number was in 2003 with 9 cases (Al-Aboud, 2004)
(Fig. 5).

Figure 5: Reported Cases of Visceral Leishmaniasis in Saudi Arabia between 1984-2004.

There are 20 different species of sand flies found in Saudi Arabia, Phlebotomus
and Sergentomyia represent the two major genera with 35% and 65% respectively (AlAboud, 2004; Doha & Samy, 2010). The Ministry of Health provides vector and reservoir
control programs in the infected areas to control the disease (WHO, 2008).

Figure 6: Map of Saudi Arabian Provinces.
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Cytochrome b5 Reductase and Drug Resistance
Emerging drug resistance in leishmaniasis is an additional problem, contributed
by enzymes (involved in the detoxification of pharmacological agents and other
xenobiotics). The patient’s immune status plays an important role in leishmaniasis drug
efficacy. The biochemical and molecular differences between Leishmania species is
responsible for the variation in the sensitivity of Leishmania species to several drugs.
Pharmacokinetics is also different from one species to the other. These variations can
complicate the treatment of leishmaniasis. Drug combination and drug monitoring play
an important role in avoiding the emergence of resistance to new drugs (Croft et al,
2006).

Figure 7: Electron Transfer by Cytochrome b5 Reductase.
Cytochrome b5 reductase enzyme transfers two electrons from NADH (electron donor) to two molecules of
cytochrome b5 (electron acceptor). These electrons then passed on to cytochrome P450, a protein with high
significance in Leishmania drug resistance and xenobiotics detoxifications. Cytochrome P450 reductase
enzyme may transfer electrons from NADPH (electron donor) to either cytochrome P450 or cytochrome b5
(donor acceptor).

Cytochrome b5 reductase (Cb5r) is a member of the ferredoxin NADP+ reductase
(FNR) family. Two NADH binding motifs, a flavin-binding motif, and a FMN/FAD
selectivity motif are the four conserved motifs in the FNR family. Cytochrome b5
reductase has a high pharmacological significance because of its essential role in fatty
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acid elongation, biosynthesis of cholesterol (humans) or ergosterol (Leishmania, fungi),
and cytochrome P450-mediated detoxification of xenobiotics. Cb5r is also important in
NADH-mediated electron transfer with cytochrome P450 as the target and electron
acceptor. It also plays an important role in erythrocyte function (Bewley et al, 2001),
(Fig. 7).

Phylogram of Cytochrome b5 Reductase
Leishmania mexicana has 7 isoforms. The ClustalW2 Multiple-Sequence
Alignment program can be used to produce a phylogram of all seven Leishmania
isoforms. As shown in the resulting phylogram below (Fig. 8), LmexCb5r-7 isoform (red
star) is the closest isoform in homology compared to the human Cb5r and fungal CBR1,
while LmexCb5r isoforms 1 and 2 (blue star) are most distant to the mammalian isoform.
Three major subclades were found: one clade containing isoforms 1, 2 and 3, asecond
clades containing isoforms 4, 5 and 6, and the clade containing LmexCb5r isoform 7
together with the human and fungal CBR1 isoforms. (Fig. 8; ClustalW2, 2012).

Nicotinamide Adenine Dinucleotide (NAD+)
NAD+ is made up of two nucleotides, adenine base and nicotinamide joined by
two phosphate groups. NAD+ is a coenzyme and has the ability to accept electrons from
other molecules and forms NADH a reducing agent to donate electrons. NAD+ can act as
a substrate of enzymes that add or remove chemical groups from proteins, which makes
NADH utilizing enzyme a target for drug discovery. (Fig.9 and 10)
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Figure 8: Phylogram of Cytochrome b5 Reductase.
ClustalW2 Multiple-Sequence Alignment program used to produce a phylogram of cytochrome b5
reductase showing that isoform 7 in LmexCb5r is the closest in homology to human Cb5r and fungal
CBR1.
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Figure 9: Nicotinamide Adenine Dinucleotide (NAD+).

Figure 10: Oxidation of NAD+.
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Isopropyl β-D-1-thiogalactopyranoside (IPTG) in Protein Expression
IPTG transcribed T7 RNA polymerase that activates T7 promoter in the
expression system. IPTG is a drug used to activate the expression of T7 RNA polymerase
located in the chromosome of the E.coli BL21 strain. It is a more useful inducer than the
lactose because it is not included in any metabolic pathways, which will prevent it from
the consumption by the cell. This will insure that the IPTG concentration added remains
constant. (Fig. 11)

Figure 11: Schematic Representation of E.coli BL21 Host Strain.
The lac promoter (Plac, red), the lac operator (locO cyan), the T7 RNA polymerase-encoding gene (T7 RNA
Pol, pink), and the lac inducer (lacI, blue) are highlighted. A black line depicts the bacterial host
chromosome in this engineered E.coli strain.
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MATERIALS AND METHODS
Gene Identification of Cytochrome b5 Reductase Isoform 7 in the L. mexicana
Genome
The gene of Cb5r isoform 7 was identified in the L.mexicana genome using the
database TriTrypDB.org (Tab. 2).
Table 2: Gene LmxM13.1060. 927bp Gene, 308 amino acid protein of LmexCb5r-7 isoform.

308 Amino Acids:
MVAVLVIIAVSMAAFFAFMFTRTTKVAMDPTMFKHFRLIKRTEVTHDTFIFRFALENEAQTLGLPIGQHIV
LRADCTTAGKTETVTHSYTPISSDDEKGYVDFMIKVYFADVHPSFPHGGRLSQHMYMKLGDKIEMRGPQGK
FIYLGNGTSRIHKPGKGVVTEKVDAYAAIAGGTGITPILQIIHAIKKNKEDPTKVFLVYGNQTERDILLRK
ELDEAVANDTRFHVWYTIDREATPEWKYDIGYVREEMFRKHPVPDMLGDDSVPQNAGIKKVMALMCGPPPM
VQMAIKPNLERIGYTADNIFNF* Theoretical pI/Mw: 8.6/34,819 Da
927bp Gene:
ATGGTCGCCGTTCTCGTCATCATCGCCGTCAGCATGGCGGCCTTCTTCGCGTTTATGTTTACGCGCACGAC
GAAGGTGGCGATGGACCCGACGATGTTCAAACATTTTAGGCTGATCAAGCGCACGGAGGTGACCCATGACA
CCTTCATCTTCCGCTTTGCCCTCGAGAACGAGGCGCAGACGCTCGGACTTCCGATCGGGCAGCACATTGTG
CTCCGCGCCGACTGCACAACGGCGGGAAAGACGGAGACAGTTACGCACTCCTACACGCCCATCTCCAGTGA
CGACGAGAAGGGCTACGTGGACTTCATGATCAAGGTGTACTTTGCCGACGTGCACCCCAGCTTCCCGCATG
GCGGCCGGCTGTCGCAGCACATGTACCACATGAAGCTCGGCGACAAGATAGAGATGCGTGGGCCGCAGGGC
AAGTTCATCTACCTGGGCAACGGCACCTCGCGCATCCACAAGCCGGGCAAGGGCGTCGTCACGGAGAAGGT
GGACGCCTATGCGGCCATCGCCGGCGGCACTGGCATCACCCCGATCCTGCAGATCATCCACGCCATCAAGA
AGAATAAGGAGGACCCGACGAAGGTGTTCCTTGTGTATGGCAACCAGACGGAGCGTGACATTCTACTGCGC
AAGGAGCTCGACGAGGCCGTCGCCAACGACACCCGCTTTCATGTATGGTACACCATCGACCGCGAGGCGAC
GCCAGAGTGGAAATATGACATTGGCTACGTCCGCGAGGAGATGTTCCGCAAGCACCTGCCCGTGCCCGACA
TGCTCGGCGACGACAGCGTGCCGCAGAACGCCGGGATCAAGAAGGTCATGGCGCTCATGTGCGGCCCACCG
CCGATGGTGCAGATGGCGATCAAGCCGAACCTGGAGCGCATCGGCTACACCGCCGATAACATCTTTAACTT
CTAA

Transmembrane Domain Analysis
In the LmexCb5r-7 protein sequence, only one transmembrane domain was
identified using the transmembrane analysis program TMpred at www.ch.EMBnet.org
(Hofmann & Stoffel, 1993). The LmexCb5r-7 transmembrane domain was spanning from

16

Met1 to Phe20 that needed to be deleted to produce soluble recombinant protein.
Therefore, a start position at threonine 21 of the LmexCb5r-7 gene was chosen as part of
the gene engineering of the gene for recombinant LmexCb5r-7 (Fig. 12).

Figure 12: Trans-membrane Domain Analysis.

Cloning of Leishmania mexicana Cb5r-7 Gene
LmexCb5r-7 gene was cloned from L.mexicana genomic DNA using PCR. Primer
design for PCR cloning of LmexCb5r-7 gene (DNA) was conducted using genomic DNA
as template for PCR. Restriction enzyme analysis of LmexCb5r-7 gene was performed to
find restriction enzymes that do not cut in the LmexCb5r-7 gene. BamH1 and Hind3 were
the restriction enzymes used in this case. Lists of the enzymes that are not found in
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LmexCb5r-7 gene are shown in (Tab. 3). Then six-histidine tag was added to the DNA
sequence at the beginning of the gene (Tab. 4).
Table 3: Non-cutting Restriction Enzymes in LmexCb5r-7.
Underlined are enzymes found in the pET23b multiple cloning site.
Aat2 Acc65 Acl1 Afe1 Afl2 Age1 Ahd1 AlwN1 Apa1 Asc1 Ase1 AsiS1 Avr2
Bae1a Bae1b BamH1 Bbs1 BbvC1 BciV1 Bcl1 BfrB1 Bgl2 Blp1 Bmr1 Bpu10
BpuE1 Bsa1 BsaB1 BsaXa BsaXb BsiW1 Bsm1 BsmB1 BspE1 BspH1 BsrB1 BsrD1
BsrG1 BssH2 BssS1 BstB1 BstX1 BstZ1 Bsu36 Bts1 BxatB BxatL BxatR BxatP
Chi Cla1 Dra1 Ear1 Eci1 Eco57 EcoK EcoN1 EcoR1 EcoRV FCatB FCatL FCatR
FCatP ScFRT Fse1 FspA1 Hind3 Hpa1 I_Ceu Kas1 Kpn1 loxP Mfe1 Mlu1 Msc1
Nar1 Nco1 Nde1 Nhe1 Not1 Nru1 Nsi1 Pac1 PflF1 PflM1 Pme1 Pml1 polyA
PshA1 Psi1 PspOM Pvu2 R4atB R4atL R4atP R4atR Rsr2 Sac2 Sal1 SanD1 Sap1
Sbf1 Sca1 SexA1 Sfi1 Sgf1 Sma1 SnaB1 SpAcc SpDon Spe1 Sph1 Srf1 Ssp1
Stu1 Swa1 T3RNA T7RNA T7Ter PISce Xba1 Xcm1
Table 4: PCR Primer Design for LmexCb5r-7.
LmexCb5r7-T21-His6-BamH1-Fwd: (891bp gene + primers = 915bp PCR band)
5’-TAGCATGGATCCATGCACCATCACCATCACCATATGACGCGCACGACGAAGGTGG-CGATG-3’
60-mer, 24-mer, 16G/C
BamH1= GGATCC
LmexCb5r7-Hind3-Rev:
5’-ACTGATAAGCTTTTAGAAGTTAAAGATGTTATCGGCGGTGT-3’
41-mer, 29-mer, 11G/C
(Fwd strand: 5’-ACACCGCCGATAACATCTTTAACTTCTAA-3’)
Hind3= AAGCTT

The end of each primer contained a specific restriction enzyme (BamH1 or Hind3,
respectively) for ligation into the multiple cloning sites of the pET23b vector. The
pET23b vector was used for protein expression. PCR primers also included the His6-tag
for protein purification. PCR product (915bp bands) is first concentrated by Na acetate
method 20μl volume, then restriction enzyme digested with BamH1 and Hind 3, and
finally purified by agarose gel electrophoresis and gel extraction (QIAquick gel
extraction kit). LmexCb5r-7 PCR band (Hind3-BamH1 digested) was inserted into pET
23b plasmid vector (Hind3-BamH1 digested) by ligation then transformed into E.coli
bacteria XL10-Gold strain for DNA work. Screening for positive colonies that contain

18

LmexCb5r-7.pET 23b (our gene in the pET 23b expression vector) was then performed
followed by restriction enzyme digest with BamH1 and Hind3. Agarose gel
electrophoresis was used to identify positive clones and confirmed by DNA sequencing.
After the confirmation, ligation product was transformed into E.coli BL 21 strain (ideal
strain for protein expression, NOT so good for DNA work). Positive clones were digested
and confirmed by sequencing (Fig. 13).

Purification of Recombinant LmexCb5r-7 Protein
One L of E.coli BL21 with positive clone was grown and protein expression was induced
with IPTG (drug to start protein expression in E.coli of our protein in pET 23b vector)
followed by overnight expression and the next day, the cell pellet was collected and
stored at -20 °C until further use for purification.
Nickel column chromatography is a common method used in protein purification.
The cell pellet was lysed using the French press technique. His6-tag was included in the
recombinant protein that allows affinity binding to Ni2+, which is part of the Ni-NTA
matrix in the column. When we loaded our recombinant protein to the column, 2 of the 6
histidines bind with one Ni2+ ion, trapping the tagged protein in the column while
unbound protein was washed out. After the washing step, we added 250mM imidazole.
This drug competes with the histidines for the Ni2+ binding interaction. This process
effectively released the recombinant protein from nickel resin and resulted in elution of
the purified recombinant protein. (Fig.14)
Size exclusion chromatography was used for additional purification of
LmexCb5r-7 (purification based on the size of our protein = 34,819 Da).
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Figure 13: pET23b Map for Cloning of LmexCb5r-7.
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Figure 14: Interaction between Neighboring Residues in the His6-tagged Protein and Ni-NTA
Matrix.

Measurement of Enzymatic Activity of Recombinant L.mexicana Cb5r-7
Enzyme activity of recombinant L.mexicana Cb5r-7 was performed by using
NADH:ferricyanide assay. NADH acts as a substrate and ferricyanide as an artificial
electron acceptor. The loss of NADH and conversion to NAD+ was measured by
spectrophotometry at 340nm. Substrate affinity (KmNADH) and catalytic rate (Kcat) of
recombinant L.mexicana Cb5r-7 was determined by the same assay.

Bradford Protein Assay
Bradford assay is a colorimetric assay. Coomassie blue dye converts from red
color (465nm) to blue (595nm) when it binds to the protein of the sample. Protein
concentration is directly proportionate to the darkness of the blue color, which can be
measured by a spectrophotometer at 595nm (Bio-Rad, 2012).
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Substrate Specificity of L.mexicana Cb5r-7
This assay used to test the inhibitor potential of the enzyme that helps in drug
discovery. ADP-Ribose, ADP, GDP, AMP, adenosine and nicotinamide (NAD analogues
competitor) and the antibiotic Novobiocin were used in the lab. The assay was performed
using the NADH:ferricyanide assay. One μl of 2.5μM protein/assay and wavelength of
340nm were used for the control. Two μl of 2.5μM protein/assay was used for all
substrate analogues. A wavelength of 370nm was used for Novobiocin and 340nm for all
other substrates.

Adenosine Diphosphate (ADP):
ADP is made up of adenine base, pentose sugar ribose and pyrophosphoric acid.
ATP synthase can convert ADP back to ATP. This conversion is important in supplying
energy (Fig. 15).

Figure 15: Adenosine Diphosphate (ADP).

Adenosine Diphosphate Ribose (ADP-Ribose):
ADP-ribose is composed of adenine base, pentose sugar, two phosphate groups
and ribose sugar molecule (Fig. 16).
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Figure 16: Adenosine Diphosphate Ribose (ADP-Ribose).

Adenosine Monophosphate (AMP):
AMP is made up of adenine, ribose sugar, and phosphate group. Adenylate kinase
enzyme can produce AMP during ATP synthesis by combining 2 ADP molecules. AMP
is used as a monomer in RNA (Fig. 17).

Figure 17: Adenosine Monophosphate (AMP).

Adenosine:
Adenosine is composed of adenine and ribose sugar molecule. It plays an
important role in energy transfer. It also acts as an inhibitory neurotransmitter (Fig. 18).

Figure 18: Adenosine.
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Nicotinamide:
Nicotinamide is a vitamin belongs to the vitamin B group (Fig. 19).

Figure 19: Nicotinamide.

Novobiocin:
Novobiocin is an aromatic ether compound composed of a benzoic acid
derivative, a coumarin residue and the sugar novobiose. Novobiocin behaves as a
competitive inhibitor of the ATPase reaction that is part of the GyrB subunit of the
topoisomerase-2 enzyme. But may also interact with Cb5r (NADH shares similar
structure with ATP) (Fig. 20).

Figure 20: Novobiocin.
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RESULTS AND DISCUSSION

PCR Amplification and Cloning of LmexCb5r-7
DNA gel electrophoresis of our PCR product resulted in a band size of 915bp,
which confirmed that we amplified the LmexCb5r-7 gene (Fig. 21).

Figure 21: Gel Electrophoresis of PCR Product LmexCb5r-7.

After running the gel for 1 hour and 30 minutes, the LmexCb5r-7 PCR band and
the pET 23b vector band were excised from the gel and weighted to determine their mass
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for subsequent gel purification by QIAquick gel extraction kit (0.470g = 470μl for
LmexCb5r-7 band gel piece; 0.400g = 400μl for pET 23b band gel piece.) (Fig. 22A,
22B).

Figure 22 A: Gel Extraction of LmexCb5r-7.
Figure 22 B: Gel Extraction of pET23b Plasmid.

Spectrophotometric analysis of quality and quantity of the purified extracted DNA
of LmexCb5r-7 and pET23b was performed according to manufacturer’s protocol for the
QIAquick gel extraction kit and showed an absorbance A260/A280 (quality check;
ideally higher than 1.8) and concentration of LmexCb5r-7 as 1.8 and 24.6 ng/μl
respectively, while the absorbance and concentration for pET23b were 1.96 and 10.6
ng/μl respectively.
Ligation was an important step for the insertion of the digested LmexCb5r-7
(Hind3 and BamH1) into the digested pET 23b plasmid vector (pET23b: 3641bp,
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LmexCb5r-7: 891bp). The ligation product was then transformed into the E.coli XL10Gold strain (best suited for DNA work).
Fourteen colonies were picked after the transformation of Z-competent cells using
E.coli XL10-Gold and subsequently digested with Xho1 restriction enzyme. Expected
bands are 3753bp for pET23b (with insert) and 779bp for LmexCb5r-7 (or 3641bp for
pET23b without successful cloning of LmexCb5r-7 insert). Four out of 14 colonies
showed positive bands after running the gel for one and a half hours and staining with
ethidium bromide (Fig. 23).

Figure 23: Gel Electrophoresis for the Digested Colonies.
Screening was performed by Xho1 digest. Expected bands are 3753bp for pET23b (with insert) and 779bp
for LmexCb5r-7 insert (or 3641bp for pET23b without successful cloning of LmexCb5r-7 insert).
Four positive colonies were identified that contained the expected LmexCb5r-7 band of 779bp (colonies 1,
3, 4 and 12).
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Measurement of Enzymatic Activity of Recombinant LmexCb5r-7 Protein
To test the activity of Cb5r enzyme, NADH was used as a substrate and its
conversion to NAD+ was measured at 340nm wavelength by a spectrophotometer. A
substrate range of 3-100 M NADH was used for kinetic analysis. Michaelis-Menten
kinetics analysis was then used to determine the affinity of the substrate (KmNADH) and the
catalytic rate (Kcat) of the recombinant lmexCb5r-7 enzyme. The plot was formed using
the Michaelis-Menten rate equation. It shows the quantitative relationship between the
initial velocity (V0), the maximum velocity (Vmax), and the initial substrate concentration
[S]. All these points are related through Michaelis constant Km, which is equal to V0= ½
Vmax. A large Km means that a high concentration of substrate was needed to achieve Vmax
and a small one required a small amount of substrate. Kcat is the maximum number of
substrate molecules converted to product on a single enzyme molecule per second
(“turnover number”). The Kcat/ Km ratio describes the overall enzyme efficiency. Low
Kcat/ Km ratio indicates that the product turnover rate is lower than the substrate
concentration, which means that the enzyme and substrate has a high affinity for each
other.
Recombinant LmexCb5r-7 enzyme had a Vmax = 38.2 ± 0.5 μmol/min/nmol
enzyme, Km = 19.3 ± 0.8 μM with a regression coefficient r = 0.9995, Kcat = 636.4 ± 8.3
sec-1 and Kcat/ Km = 33.0 x 106 sec-1 M-1 (Fig. 24).
The comparison of the initial-rate enzyme kinetics between LmexCb5r-7 and
human Cb5r enzyme showed that they have similar affinity, twice the catalytic rate but
about the same catalytic efficiency (Tab.5).
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Table 5: Comparison of Initial-rate Enzyme Kinetics of LmexCb5r-7 with Human Cb5r Enzyme.

Kcat

(sec )

Km
(μM)

(sec M )

636 ± 8.3

19.3 ± 0.8

33.0 x 10

-1

LmexCb5r-7
Human Cb5r

328 ± 7

13 ± 0.9

Kcat/Km
-1

-1

6

25.3 x 10

6

Vmax
(μmol/min/nmol)
38.2 ± 0.5
19.7 ± 0.4

Recombinant LmexCb5r enzyme provides a promising target in rational drug
design and drug screening against Leishmania.

Figure 24: LmexCb5r-7 Kinetics with the NADH:Ferricyanide Assay.
Michaelis-Menten Kinetics showed a Vmax = 38.2 ± 0.5 μmol/min/nmol enzyme, a Km = 19.3 ± 0.8 μM with
a regression coefficient r = 0.9995, a Kcat = 636.4 ± 8.3 sec-1 and a Kcat/ Km = 33.0 x 106 sec-1 M-1.
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Bradford Protein Assay
The Bradford assay was performed to determine the protein concentration in our
samples. His6-Thr21-LmexCb5r-7 protein concentration was 38.1 mg/ml using the
Bradford

assay

vs.

22.8

mg/ml

using

the

spectrophotometer

assay.

The

spectrophotometer assay measures Cb5r flavin, which makes this assay more specific and
accurate for Cb5r determination compared to the Bradford assay that uses bovine serum
albumin (BSA) as protein standard. From this experiment we developed a conversion
equation (Spectrophotometer Cb5r protein concentration by [FAD] x 1.70 = Bradford
Cb5r protein concentration) (Fig. 25).

Figure 25: Bradford Protein Assay.

LmexCb5r-7 Substrate Analogues
This experiment was testing the inhibition potential on the enzyme that will help
in drug discovery. Six NAD analogues and the antibiotic Novobiocin were tested for
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LmexCb5r-7 using the NADH:ferricyanide assay. These six NAD substrate analogues are
used as lead drugs for subsequent design.
ADP and Novobiocin showed the highest inhibition effect with 80% (LmexCb5r7) compared to 82% (human Cb5r) inhibition by ADP and 77% (LmexCb5r-7) compared
to 89% (human Cb5r) inhibition by Novobiocin. Human Cb5r and LmexCb5r-7 showed
almost the same inhibition profile, therefore we would need to test their inhibition in live
Leishmania cells (macrophages or in-vitro testing for Leishmania parasite) to better
characterize the individual drug inhibition effects on the parasite compared with the
mammalian host (Fig. 26).

Figure 26: L.mexicana Cb5r-7 and Human Cb5r Substrate Specificity.
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LIGPLOT Analysis of Cb5r-NAD Enzyme-Substrate Interaction
LIGPLOT for rat Cb5r interaction with NAD was generated from the crystal
structure of enzyme that forms 5 hydrogen bonds and 12 hydrophobic interactions
between protein and ligand NAD (Wallace et al., 1995; Wallace & Laskowski, 2005),
(Fig. 27).
LmexCb5r-7 has the same LIGPLOT analysis results of rat Cb5r-NAD enzymesubstrate interactions except for alanine 208 in rat that is changed to glycine 203 in
LmexCb5r-7 at the nicotinamide moiety interaction of Cb5r-NAD enzyme-substrate and
phenylalanine 251 in rat that is changed to tyrosine 246 in LmexCb5r-7 interacting with
the adenine purine ring of the NAD substrate. The interaction between protein and ligand
NAD is particularly important in drug design when using substrate analogues as potential
drugs.

Figure 27: LIGPLOT Analysis of Cb5r-NAD Interaction.
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SUMMARY
Leishmaniasis is an important disease with worldwide distribution. This disease
can be fatal if untreated. The existing drugs are very toxic and strong side effects lead to
the urgent need to develop new drugs. Cytochrome b5 reductase is an enzyme involved in
fatty acid elongation and ergosterol biosynthesis in Leishmania. Cb5r is also important in
NADH-mediated electron transfer with cytochrome P450 as the target and electron
acceptor that can neutralize drugs and xenobiotics. A phylogram was generated using the
ClustalW2 program to align the amino acid sequences of Leishmania, human and fungal
Cb5r enzymes. From the seven isoforms of LmexCb5r, LmexCb5r-7 showed the closest
homology to humanCb5r and fungal CBR1. The Cb5r isoform 7 gene was identified in
the Leishmania mexicana genome using the TriTrypDB.org database. Subsequently, a
single transmembrane domain was identified in LmexCb5r-7 using a transmembrane
domain analysis program, spanning 20 amino acids from Met1 to Phe20 that had to be
removed for the cloning approach to produce a soluble recombinant protein. Genomic
DNA was used as template for PCR cloning of the LmexCb5r-7 gene since this gene does
not contain any introns. As part of the cloning strategy, restriction enzyme analysis of
LmexCb5r-7 gene was performed and BamH1 and Hind3 were selected for cloning.
Additionally, a 6-histidine tag was added to the beginning of the gene for nickel column
purification. The digested LmexCb5r-7 PCR band (Hind3-BamH1) was then inserted into
the digested pET23b plasmid vector (Hind3-BamH1) by ligation followed by
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transformation into the E.coli XL10-Gold strain. Screening, identification and
confirmation of positive clones was performed and confirmed by DNA sequencing.
Recombinant LmexCb5r-7 protein expression was conducted by transforming the
positive clone into the E.coli BL21 strain optimized for IPTG-inducible protein
expression for subsequent purification by nickel column chromatography. Enzyme
activity

of

recombinant

LmexCb5r-7

protein

was

measured

by

using

the

NADH:ferricyanide assay, where NADH acts as a substrate and ferricyanide is used as an
artificial electron acceptor. Loss of NADH was measured by spectrophotometry at
340nm. Enzyme kinetics were performed that resulted in a substrate affinity (Km) of 19.3
± 0.8 μM, catalytic rate (Kcat) 636.4 ± 8.3 sec-1, maximum velocity (Vmax) 38.2 ± 0.5
μmol/min/nmol enzyme, and Kcat/ Km = 33.0 x 106 sec-1 M-1 of recombinant LmexCb5r-7.
The initial rate enzyme kinetics of LmexCb5r-7 enzyme was compared to the human
Cb5r enzyme and the results showed that they have similar affinity, twice the catalytic
rate, but about the same catalytic efficiency. Six NAD analogues (ADP-Ribose, ADP,
GDP, AMP, adenosine and nicotinamide which act as substrate competitors) and the
antibiotic Novobiocin were tested for LmexCb5r-7 and compared to the human Cb5r
enzyme. These inhibitor assays were used as a first step to characterize LmexCb5r
isoforms as a potential drug target. ADP and Novobiocin showed the highest inhibition
effect with 80% (LmexCb5r-7) compared to 82% (human Cb5r) inhibition by ADP and
77% (LmexCb5r-7) compared to 89% (human Cb5r) inhibition by Novobiocin. ADP and
Novobiocin showed similar activity on both human Cb5r and LmexCb5r-7. The next step
would be to test their activity in live cells (in macrophage infectivity assays or in-vitro for
Leishmania parasites) to characterize their inhibitory effects in more detail. A LIGPLOT
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analysis for Cb5r was generated in silico that showed the interactions between protein
and ligand NAD at the atomic level. The comparison of the amino acid interaction with
the substrate NAD in LmexCb5r-7 LIGPLOT and rat Cb5r LIGPLOT were similar
except for two amino acid changes: Alanine 208 to glycine 203 substitution in
LmexCb5r-7 at the nicotinamide binding moiety and phenylalanine 251 to tyrosine 246
substitution in LmexCb5r-7 at the adenine purine ring binding moiety of Cb5r-NAD
enzyme-substrate interaction. The protein:NAD ligand interactions play an important role
in subsequent drug design. While LmexCb5r-7 is the isoform with closest homology to
human Cb5r, the LmexCb5r isoforms 1 and 2 are most distant from the human enzyme,
which makes LmexCb5r-1 and 2 enzymes the best target for future rational drug design
and drug screening against Leishmania Cb5r.
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FUTURE DIRECTIONS

Cloning and characterization of all seven Leishmania mexicana Cb5r isoforms
and comparison of the different isoforms with respect to the enzyme activity (kinetics,
substrate affinity), pharmacology and differential expression in insect or mammalian
stage of the parasite. Another step would be to generate LmexCb5r knockout cells for
each isoform in Leishmania parasites and test them for their effect on survival in
macrophage infectivity assays. Furthermore, performing structure-function analysis of
Cb5r isoforms would be another strategy for rational drug design and pharmacological
characterization of Leishmania Cb5r.
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APPENDICES
Appendix A: Protocols
Protocol 1:
Large-Scale Protein Purification of Recombinant Proteins
A.

Growth of Bacterial Cultures and Induction with IPTG

Day 1: Set up an overnight broth in 4mL Terrific broth-Amp75 (completed by 5:00 p.m.
for appropriate overnight growth).
1. Setting up the large broths requires these components in set amounts:
 50.8 g/L of Terrific Broth powder medium
 4 mL of glycerol
 38 mg/L of riboflavin
 1L of de-ionized water
2. Once all broth has been mixed, it is ready to be placed in the autoclave (liquid
setting, 20 min. @ autoclaving pressure & temperature, 15 min. total)
 after autoclaving and cooling of broth to room temperature, add: Amp
 5 mL/L Ampicillin stock (15 mg/mL stock in 50% EtOH, -20°C)
3. Sterile procedure: The 4mL broth can be found in the 4°C refrigerator with the
appropriate labeling (Terrific broth with Amp, in a 100mL rectangular bottle).
In the sterile tissue culture hood, aspirate 4 mL from this stock broth and aliquot
2mL each to two sterile test tubes.
4. Inoculate the 4 mL overnight broth with your stabilate of choice (stored in -80°C
freezer in hallway). To do this, take a 1mL sterile pipette and stab the top of the
frozen stabilate to procure a few cells in and around the pipette tip (use about as
much force as you would tapping your fingers on a desk). Immerse the tip, now
harboring cells, into each of the 2mL broth-containing test tubes. Leave these test
tubes overnight in the incubator around the other side of the hallway (windows
facing Busch Gardens). The incubator should be left shaking 220 RPM @ 37 °C.
5. Leave overnight shaking
Day 2: (10:00-11:00 a.m.) In the hood: Add all 4mL of o/n broth to 36mL pre-warmed
Terrific broth-Amp75 combined in a small, sterile, baffled flask – the ones on the shelf
over the PCR and scales). Return this 40mL total starter culture to the same incubator
where the test tubes were placed overnight. Allow the culture to grow for ~2-3 hours.
1. (~12:30 p.m.) One hour before inoculating larger broths, put broths at 37°C with
shaking to pre-warm the media (incubator down the hall in autoclave/rotor room).
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2. (~1:30 p.m.) Before inoculating, take 1mL of broth from a 1L broth for OD600
blank. Then, in the hood, inoculate 1000mL Terrific broth-Amp75-100µM
riboflavin with 10mL starter culture/each (usually grow 4L total) and grow until
OD600 = 0.5-0.8. (doubling time 45-50 min)
 OD = cell density @ 600 nm
 Use 1 mL of broth for blank
3. (~4:00 p.m.) Check the OD. If it has reached the appropriate density, begin the
induction: Add 0.2mM IPTG (2mL 100mM IPTG stock per 1000mL).
 Put cultures back at 37°C for 20 minutes. Then,
4. Incubate at room temperature overnight ~220 RPM.
 Leave overnight: Overnight expression at room temperature is better than 3
hours at 37°C.
Day 3: (10:00 a.m.) Take OD600 of overnight broth (make a 1:10 dilution [900 µL pure
broth (can be from blank) + 100 µL overnight broth culture], to bring the solution into a
measurable range: OD <1). This is to monitor density and possibly calculate doubling
times.
1. Transfer each 1000mL broth into large bottles (caramel colored screw-on caps on
shelf over the scales) for centrifugation. Centrifuge 30 minutes at 3,500 RPM at
4°C in a JLA8.1000 rotor
(Beckman Avanti J-20, 3rd floor common room: it has a foot pedal to open it. The
various rotors are on the shelf by the cold room. This process requires the largest
rotor which has silver rimmed wells - the only ones big enough to fit the large
bottles).
2. After centrifugation, the supernatant should be almost clear. It will be the
honey/tea color of the original broth with no colloidal appearance (cells should be
aggregated at the bottom). Decant the supernatant in the corner sink of our lab, by
the Eppendorf centrifuge.
3. Resuspend pellet by:
 Adding 10mL COLD 1x PBS and resuspending with a transfer pipet to a
50mL conical tube (best performed with PBS on ice; keep the samples on ice
as well – three ice buckets are ideal but two buckets with alternation of the
samples will suffice).
 Rinse bottles with another 10mL PBS and transfer to same 50mL conical tube
4. Centrifuge 3,500 RPM (~2,500 x g) 20 minutes at 4°C (Eppendorf centrifuge).
5. Decant supernatant.
6. Freeze the pellet (about 5-10mL per 1 L culture) at -20°C until further use.
CANNOT FREEZE PROTEIN AFTER THIS POINT, once cells are lysed
B.

Use French Press to Obtain Bacterial Cell Lysate
1. Add 25mL lysis buffer to each pellet (make sure to do this individually).
2. Add 25µL 50mM PMSF to each sample (50mM PMSF as 1000x fold stock, will
give 50µM)
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3. Use French Press in Ferreira Lab on second floor according to instructions. Run
each 30mL sample twice through French Press.
4. Spin 12,000 x g (~10,000 RPM) 15 minutes at 4°C in JA-20 rotor (autoclave
room, 3rd floor). Use round-bottom bicarbonate tubes.
C.

Nickel Resin Binding

NOTE: Use 1/5 volume nickel resin to supernatant sample (25mL supernatant will need
10mL resin (5mL gel bed)
1. Spin down nickel resin at 500 x g (1576 RPM) for 2 minutes at 4°C to obtain gel
bed. Decant liquid portion (retain resin).
2. Wash nickel resin (if using new batch from Qiagen bottle) to equilibrate with lysis
buffer by adding 5mL lysis buffer and spin as before. Repeat 2x (3x total). Decant
liquid (should be 5mL gel bed).
Resuspend in 5mL lysis buffer (10mL total because gel bed=5mL)
3. Add each 25mL cell lysate sample to 5mL resin in 50 mL conical tube
4. Add 50µM PMSF to each sample (50µL from 50mM stock, 25µL/sample)
5. Rotate for 1 hour at 4°C. (on belly dancer in the fridge)
6. Spin down 2,000 x g (~3000 RPM) for 5 minutes at 4°C
7. Decant (pour out supernatant) liquid portion, retaining resin with bound protein at
bottom of tube.
8. Wash by adding 5mL lysis buffer to each sample, capping conical tube, and
inverting several times to mix (or flick, agitate the bottom of the conical).
Centrifuge 500 x g for 2 minutes at 4°C. Decant liquid portion. Repeat for a total
of 10 washes.
Preparation of nickel resin column:
9. Add 1mL lysis buffer to empty blue column to equilibrate column.
10. Add all resin-sample mixture to column and let it flow through by gravity (waste).
This is the blue column. Pour slowly down the side to not disturb the resin
11. Elute with ~10-15mL of elution buffer (imidizole elution buffer) by gravity.
D.
1.
2.
3.
4.
E.
1.

Concentration of Samples
Use Amicon Ultra-4 Ultracel-10K (proteins less than 10 kDa flow through,
including imidazole).
Equilibrate Amicon membrane by adding 1mL lysis buffer and spinning at 3400
RPM 4°C for 10 minutes.
Add samples to Amicon concentrator. For a 5mL sample per Amicon tube,
centrifuge 10 minutes at 3400 RPM 4°C. There should be ~500µL left. If there is
more liquid, spin an additional few minutes.
Use 100L of lysis buffer to get remaining protein from the inside of the
membrane with a small pipette
Size Exclusion Chromatography
Make sure the Superdex 75 column has been equilibrated with the corresponding
buffer (stock TBS)!
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2.
3.
4.
5.
6.
7.

8.

Yellow skinny column holding only 7 mL
Add buffer to the reservoir chamber and turn on peristaltic pump to 1mL/min
setting to run fresh buffer through the column. Do this for ~ 5 minutes.
Add all of the nickel column elution (concentrated to ~0.5mL) to the column
apparatus.
Use a small pipette to slowly add the elution, so as not to disturb the SE column
Watch for yellow elution of cb5r running through the column. Collect samples ~5
minutes before and after yellow color is seen.
Concentrate samples as previously described in Section D. The sample volume
can range from 250-500µL, depending on how concentrated you want it.
Centrifuge for 20 minutes (for 2 mL) x 3500 rpm to get the 0.5 mL of the flavin
containing protein
At this point, you can perform spectral analysis to see if bound-flavin peak at
461nm and characteristic shoulder at 480nm is visible for cb5r samples. (Set up a
1:100 dilution using TBS buffer and see protocol on Spectral Analysis).

Freeze sample in liquid nitrogen by pipetting drop wise into a liquid nitrogen bath.
Store at -70°C.
 Use 100 μL per pipet to make the protein beads (each drop will be about 10-15
L)
 Freeze immediately in the -70°C freezer (in hallway, top shelf, in recombinant
protein box)
TBS Buffer (For Equilibration and Lysis Buffers)
50mM Tris
6.057g Trizma base
200mM NaCl
11.688g NaCl
Dissolve in 950mL water and pH to 8.0 with HCl. Bring up to 1000mL and filter
sterilize.
2X Stock TBS Buffer (For Elution Buffer)
100mM Tris
1.2114g
400mM NaCl
2.3376g
Add to 100mL water and pH to 8.0 with HCl. Filter sterilize.
Lysis Buffer
(Makes 100mL)
50mM Tris
200mM NaCl
20mM Imidazole
(4mL of 500mM stock)
0.2mM EDTA
(40µL of 0.5M stock)
0.1% Triton-X 100 (1mL of 10% stock)
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Protocol 2:
Kinetics and Biochemical Assays
A. Spectral Analysis Using UV Absorbance
1.
2.
3.
4.
5.
6.
7.

Start up computer connected to HP8453 UV-Vis Spectrometer
Use wavelengths:
272nm and 461nm
Background correction:
‘substrate average over range’ 800-900nm
Data type:
Absorbance
Display spectrum:
from 250 to 750nm
Turn on UV and Tungsten lamps
Make a blank of absorbance with 200 μl of 10 mM KPi buffer in quartz cuvette
labeled 6Q
8. Prepare 1:8 dilution of protein sample (25 μl sample + 175 μl 10mM KPi buffer:
10 mM KH2PO4, 0.1 mM EDTA, pH 7.0)
9. Mix sample in cuvette and place it in the spectrophotomer, then click ‘sample’
10. Record Net 272nm, Net 461nm
Purity =

Net 272nm___
Net 461nm

Concentration =

Net 461nm__
10.6

B. Kinetics and Activity Assay (UV-2101PC Spectrophotometer)
1. Turn UV Spectrophotometer on first, then turn on the computer
2. Set up spectrophotometer parameters as followed
Acquire Mode - Time Course
Configure – Parameters:
Low:
-0.100
High:
1.300
Wavelength:
340 nm
Slit width:
20nm
Timing mode:
auto
Reaction time:
60 sec
C. For ACTIVITY assay, follow this pipette order:
o
o
o
o
o
o
o
o
o
o

974 µL MOPS
Insert stir bar
15 µL K3Fe(CN)6
Click ‘Auto Zero’ – 340nm absorbance should be ~0.000
10 µL NADH (10 mM stock) – 340nm absorbance should be ~0.622
Add 1 µL 5µM protein stock and immediately click START
Record 40 seconds of activity
Save the data with a suitable 3 character name
Click Manipulate at Data Print and select your data file
Highlight from 8 seconds until 38 seconds and click Edit and Copy
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o Paste into the Excel Template and record column G (activity rate) and the
b intercept from the graph (initial NADH absorption)
D. For INHIBITOR assay, follow this pipette order:
o
o
o
o
o
o
o
o
o
o
o
o

924 µL MOPS
Insert stir bar
15 µL K3Fe(CN)6
50 µL Inhibitor
Click ‘Auto Zero’ – 340nm absorbance should be ~0.000
10 µL NADH (10 mM stock) – 340nm absorbance should be ~0.622
Add 1 µL 5µM protein stock and immediately click START
Record 40 seconds of activity
Save the data with a suitable 3 character name
Click Manipulate at Data Print and select your data file
Highlight from 8 seconds until 38 seconds and click Edit and Copy
Paste into the Excel Template and record column G (activity rate) and the
b intercept from the graph (initial NADH absorption).
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Appendix B: Permissions
CDC Permission:
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